Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (625)	3/7/2004 5:05:10 PM
From: Miljenko Zuanic	Respond to of 1022

Erik, I think that anti-CTLA-4 is valuable play, and MEDX may have here something of value. However, is their IP right (from GILD-NXTR) sufficient to stop competitor(s), I do not know. For instance we have several controversy reports on IMCL IP right on anti-EGFR antibody/chemo combination. While I will side with those who think that IMCL IP right is not so strong, AMGN action to move single agent ABX-EGF into pivotal trial suggest that they are AFRAID of the possible IMCL action. Also, initially IMCL tried to push combination as ONLY options in using anti-EGF antibody (one of the reason that FDA rejected initial NDA). So, transplanted to MEDX anti-CTLA-4 IP right, it will be interesting to see (and follow) what potential competitors are doing here??? Miljenko